We used metformin, DAPT, and evodiamine in the murine tumor model to demonstrate that KLF10, the Notch signaling pathway and Notch-3 are potential therapeutic targets in PDAC with KLF10 deficiency. This evidence concerns the gene NOTCH3 and neoplasm.